Cipla

Cipla Assets per Share

The Total Assets per Share of Cipla (CIPLA.NS) as of Nov 4, 2026 is 525.81 INR. In the previous year, Total Assets per Share was 462.60 INR — a change of 13.67% (higher).

Assets per Share

525.81INR

YoY

13.67%

Last updated:

Total Assets per Share of Cipla is 2026 525.81 INR. Total Assets per Share of Cipla was 2025 462.60 INR. It decreases by 13.67% higher compared to the previous year.

The Cipla Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2019
296.50 INR
Jan 1, 2020
292.78 INR
Jan 1, 2021
311.21 INR
Jan 1, 2022
335.33 INR
Jan 1, 2023
364.56 INR
Jan 1, 2024
404.83 INR
Jan 1, 2025
462.60 INR
Jan 1, 2026
525.81 INR
The Cipla Assets per Share history
YEARAssets per ShareYoY
525.81INR+13.67%
462.60INR+14.27%
404.83INR+11.05%
364.56INR+8.72%
335.33INR+7.75%
311.21INR+6.29%
292.78INR-1.26%
296.50INR+4.82%
282.86INR+8.67%
260.30INR-0.43%
261.42INR+34.42%
194.48INR+17.27%
165.84INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cipla stock

Total Assets per Share of Cipla is 525.81 INR in 2026.

Total Assets per Share of Cipla changed from 462.60 INR to 525.81 INR, representing a 13.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Cipla since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Cipla

All Key Metrics — Cipla